COVAXIN is India’s ‘first’ indigenous COVID-19 antibody, created by Hyderabad-based Bharat Biotech in a joint effort with ICMR and NIV.
Indian specialists have given the green light to test Bharat Biotech’s COVID-19 antibody in Phase I and Phase II clinical preliminaries.
India’s first potential COVID-19 antibody has been given endorsement for Phase I and Phase II clinical preliminaries. Named COVAXIN™, the immunization was created by Bharat Biotech and has been allowed endorsement from the Drugs Controller General of India (DCGI). Human clinical preliminaries are booked to begin across India in July 2020
Bharat Biotech made COVAXIN in a joint effort with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV). As indicated by the organization, the SARS-CoV-2 strain was confined in NIV, Pune and moved to Bharat Biotech. The indigenous, inactivated immunization was created and made in Bharat Biotech’s office situated in Hyderabad, India.
The DCGI conceded consent to start Phase I and II human clinical preliminaries after the organization submitted results created from pre-clinical investigations, illustrating “promising” and “broad” security and safe reactions.
Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech, stated: “We are pleased to declare COVAXIN, India’s first indigenous immunization against COVID-19. The coordinated effort with ICMR and NIV was instrumental in the improvement of this immunization.
The proactive help and direction from CDSCO has empowered endorsements to this task. Our R&D and assembling groups worked energetically to send our exclusive innovations towards this stage.
The COVID-19 Antibody Detection Kit Market 2021 research report gives emerging industry data, global segments and regional outlook.
The report generated using various analysis tools like porter’s five forces model, market attractiveness and value chain.
The report gives comprehensive review of the global market helping to club revenue generation and profitable business to transform client’s success.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the COVID-19 antibody detection kit market include Cellex, Abbott, Roche, BioMedomics, BD, Henry Schein, Safecare Bio-Tech, Others.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global COVID-19 Antibody Detection Kit Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/covid-19-antibody-detection-kit-market/download-sampleMarket DynamicsMassively rising cases of coronavirus worldwide will be the main driving factor for the growth of this market.
An increase in government approvals for novel antibody test kits will boost market growth.
We conduct an accurate and reliable COVID Test.
Our qualified phlebotomists trained for safe and hygienic sample collecting during Test for COVID 19.
We are the most trustworthy lab for COVID 19 testing in India.
Get your COVID-19 Test done with Metropolis Healthcare.
Medical PPE Resource is the leading COVID-19 antibody rapid test kit distributor that offers genuine products that will make testing easier.
Our kits are made to offer accurate results when used properly.
We supply Rapid Response PCR, Antibody and antigen COVID-19 tests and personal protective equipment (PPE) supplies and much more through our well-established supply chain.
We are one of the leading distributors of COVID-19 test kits that have high sensitivity and accuracy.
We aim to assist in the fight against the coronavirus pandemic.
With the increasing demand for COVID-19 rapid test kits, we can supply small along with large quantities.
